top of page

ZERO Biotech Achieves Hong Kong's Zero-to-One Breakthrough: Top CAS Radiopharmaceutical Technology First-Everly Transferred to HK Biomedical Startup

5 Nov 2025

ZERO Biotech was thrilled to host the "IGNITING THE FUTURE OF NUCLEAR MEDICINE" forum on 5/11/2025 at Hong Kong Science Park.  


ree

ree

The highlight of the event was the signing of three critical agreements that mark a significant step in our strategy to "integrate into the national development blueprint" [融入國家發展大局]  and "Bring In, Go Global." [引進來、走出去]  These collaborations will accelerate the translation of world-class science into life-saving therapies:


ree

  1. Technology Transfer Agreement with Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM, CAS): Introducing the latest FAPI-based theranostic molecule to revolutionize treatment for prevalent Asian cancers. The vision is clear: one radiopharmaceutical drug to potentially address multiple cancer types, bringing hope to countless patients.


ree

  1. Cooperation Agreement with New Frontier Group: Expanding the implementation of these advanced FAPI-based applications across the Greater Bay Area (GBA) and Mainland China, fast-tracking the cross-border translation of Hong Kong's scientific achievements.


ree

  1. Partnership and Supply Agreement with TerThera: Securing a stable, next-generation supply chain as the global exclusive supplier of GMP-grade Tb-161 (Terbium-161), reinforcing its leading position in radiotheranostics.



The event also invited two academic and industry leaders to share the latest trends and business opportunities in radiopharmaceuticals. 


ree

Professor Zhen Cheng Director, Molecular Imaging Center, SIMM-CAS "Innovation of Radiopharmaceutical Development and Clinical Translation"



ree

Professor Thomas Leung 

Director of Clinical Trial Centre and Associate Director of Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital

"Theranostics: Current Applications and Future Potential"


We believe Hong Kong is well-positioned to become the regional hub for nuclear medicine, and we are proud to contribute to this growing ecosystem. Our sincere thanks go to our partners and the participating government bureaux for their support—together, we can continue building this dynamic and impactful community.


ree

Media Coverage : 香港經濟日報明報

Address

3/F Tien Chu Commercial Bld

173 Gloucester Road

Wan Chai, Hong Kong

General Inquiries

bottom of page